A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2018 Planned End Date changed from 6 Jan 2020 to 25 Aug 2020.
- 31 Jul 2018 Planned primary completion date changed from 6 Jan 2020 to 25 Aug 2020.